What is the 13F Pro Quality Score for ABT?

13F Pro ranks ABBOTT LABORATORIES (ABT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABT's current score at https://13fpro.ai/company/ABT (free sign-up required for the full ranking).

Which hedge funds own the most ABT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABT include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ABT as soon as new 13F filings post.

Where does 13F Pro source ABT data?

All ABBOTT LABORATORIES fundamentals and ownership data come directly from SEC EDGAR. ABBOTT LABORATORIES files with the SEC under CIK 1800. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABT in?

ABBOTT LABORATORIES (ABT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ABT's revenue?

Per ABBOTT LABORATORIES's latest 10-Q filed with the SEC on 2026-07-28, the biggest revenue drivers are: Medical Devices ($5,853M, +9.0% YoY); Diabetes Care ($2,188M); Diagnostic Products ($3,092M, +42.3% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ABT.

What are ABT's largest expenses?

ABBOTT LABORATORIES's latest 10-Q reports these as the largest expense items: Cost of products sold, excluding amortization ($5,325M, vs $4,854M prior year); Selling, general, and administrative ($4,025M, +30.3% YoY); Research and development ($892M, +22.9% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is ABT research updated on 13F Pro?

ABT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ABBOTT LABORATORIES(ABT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1800 ABT stock profile & AI dashboard →

13F Pro Quality Score

65.5/100

Rank #475 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

45.9/100

Profitability

60.0/100

Balance Sheet

75.6/100

Earnings Quality

74.3/100

Free Cash Flow

67.4/100

Institutional Flow

55.5/100

Revenue Scale

96.7/100

Dilution Risk

46.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ABT Scores 66/100

exact factor attribution · 2026-09-11

ABT's composite is driven by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.0 pts

97th pct

Free cash flow

+2.6 pts

67th pct

Capital efficiency

+2.6 pts

76th pct

Earnings quality

+2.4 pts

74th pct

Profitability

+1.5 pts

60th pct

Institutional flow

+0.3 pts

56th pct

Earnings growth

+0.1 pts

53th pct

Shareholder dilution

-0.2 pts

46th pct

Revenue growth

-0.8 pts

46th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ABT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ABBOTT LABORATORIES (ABT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABT at 65.5/100 on a 32-signal composite quality model, placing it at rank #475 of 2,962 stocks — the top 25% of the AI-ranked universe. ABT scores in the top quartile across revenue scale (96.7), balance sheet strength (75.6). Shareholder dilution risk is elevated at 46.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ABBOTT LABORATORIES reports quarterly revenue of $11.2B, net income of $1.1B, an operating margin of 12.0%. Top institutional holders of ABT by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABT trades on the NYSE exchange and files with the SEC under CIK 1800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABBOTT LABORATORIES directly from SEC EDGAR. ABBOTT LABORATORIES's 13F Pro composite quality score has ranged between 60 and 79 since 2021, currently 65.5 — a stable long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about ABBOTT LABORATORIES

Quirks, history, and lore behind ABT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in northern Illinois.
2
The Numbers
Annual revenue around $20 billion, spread across four business segments including medical devices, diagnostics, nutrition, and branded generics.
3
The History
Founded in 1888 by a Chicago pharmacist, it spent over a century as a pharmaceutical giant before spinning off its pharma division as a separate company in 2013.
4
The Secret
That spinoff became one of the world's best-selling drug companies — but the parent kept the diagnostics and devices businesses and quietly became a pandemic testing powerhouse.
5
The Lore
Its rapid COVID-19 tests were everywhere in 2020–21, and its BinaxNOW card became as recognizable as a thermometer; it also makes the FreeStyle Libre glucose monitor beloved by diabetics worldwide.
6
The Giveaway
It spun off AbbVie (home of Humira), kept the diagnostics and nutrition arms — including Similac baby formula — and trades under a three-letter ticker that sounds like a London pub shorthand.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ABT's Business? Latest 10-Q Breakdown

✓ 39/39 datapoints verified

AI-extracted from ABBOTT LABORATORIES's 10-Q filed 2026-07-28 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 13.0% to $12.6B on the $20.6B Exact Sciences acquisition, but net earnings fell to $928M from $1,779M as deal costs, amortization, and interest expense surged.

Biggest Revenue Drivers

Medical Devices$5,853M+9.0% YoY

High single-digit growth in Medical Devices; +7.9% excluding foreign exchange

Diagnostic Products$3,092M+42.3% YoY

Driven by the Exact Sciences acquisition completed March 23, 2026, reported as Cancer Diagnostics

Biggest Revenue Drivers

Total revenue: $12,593M+13.0% YoY

Medical Devices$5,853M+9.0% YoY

High single-digit growth in Medical Devices; +7.9% excluding foreign exchange

Within Medical Devices

Diabetes Care$2,188M

Continued growth in continuous glucose monitoring systems in the U.S. and internationally

Diagnostic Products$3,092M+42.3% YoY

Driven by the Exact Sciences acquisition completed March 23, 2026, reported as Cancer Diagnostics

Within Diagnostic Products

Cancer Diagnostics$919M

Exact Sciences sales, including Cologuard, Oncotype DX, and Cancerguard, since acquisition

Nutritional Products$2,144M-3.1% YoY

Lower sales volumes across adult nutritional and U.S. pediatric product portfolios

Largest Expense Items

Cost of products sold, excluding amortization$5,325Mvs $4,854M prior year

Unfavorable impact of higher costs, partially offset by favorable business mix and margin improvement initiatives

Selling, general, and administrative$4,025M+30.3% YoY

Addition of Exact Sciences and integration expenses, higher legal reserves, increased selling and marketing spend, unfavorable foreign exchange

Research and development$892M+22.9% YoY

Addition of the Exact Sciences business and continued investment in development programs across multiple businesses

Amortization of intangible assets$658Mvs $420M prior year

Higher intangible amortization related to the Exact Sciences acquisition

Margins: Gross margin was 52.5% in Q2 2026 versus 52.7% a year earlier, reflecting higher Exact Sciences intangible amortization and higher costs, partly offset by favorable mix and margin initiatives.

Watch Items from the Filing

Exact Sciences bought for $20.6B, funded with $20.0B of new debt; long-term debt rose to $29.6B from $9.9B and net interest expense hit $299M versus $50M.
Missouri Court of Appeals affirmed the $495M NEC infant-formula verdict in May 2026; Abbott cannot estimate a loss range and has recorded no reserves.
Rapid and Molecular Diagnostics sales fell to $755M from $815M, down 8.8% for six months excluding FX on weaker respiratory virus season.
IRS Statutory Notices of Deficiency total $417M (2019), $192M (2017-2018), and $443M (2020); a $413M Malaysian assessment was upheld and is under appeal.
Goodwill of $35.2B and net intangibles of $17.2B now equal roughly half of $109.2B total assets; purchase price allocation is preliminary and could change materially.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$11.2B

Net Income

Q1 2026

$1.1B

Free Cash Flow

Q1 2026

$916.0M

Operating Margin

Q1 2026

12.0%

ROIC

Q1 2026

6.3%

D/E Ratio

Q1 2026

0.65

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+5.7% YoY

$44.33BFY 2025

FY22 $43.65BFY23 $40.11BFY24 $41.95BFY25 $44.33B

Net Income

-51.3% YoY

$6.52BFY 2025

FY22 $6.93BFY23 $5.72BFY24 $13.40BFY25 $6.52B

Operating Income

+18.0% YoY

$8.05BFY 2025

FY22 $8.36BFY23 $6.48BFY24 $6.83BFY25 $8.05B

EPS (Diluted)

-51.3% YoY

$3.72FY 2025

FY22 $3.91FY23 $3.26FY24 $7.64FY25 $3.72

Total Assets

+6.5% YoY

$86.71BFY 2025

FY22 $74.44BFY23 $73.21BFY24 $81.41BFY25 $86.71B

Total Debt

+2.2% YoY

$15.96BFY 2025

FY22 $19.02BFY23 $15.76BFY24 $15.63BFY25 $15.96B

Op. Cash Flow

+11.8% YoY

$9.57BFY 2025

FY22 $9.58BFY23 $7.26BFY24 $8.56BFY25 $9.57B

Free Cash Flow

+16.4% YoY

$7.39BFY 2025

FY22 $7.80BFY23 $5.06BFY24 $6.35BFY25 $7.39B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$44.33B +5.7%	$41.95B +4.6%	$40.11B -8.1%	$43.65B +1.3%	$43.08B +24.5%	$34.61B
Net Income	$6.52B -51.3%	$13.40B +134.2%	$5.72B -17.5%	$6.93B -2.0%	$7.07B +57.3%	$4.50B
Operating Income	$8.05B +18.0%	$6.83B +5.4%	$6.48B -22.5%	$8.36B -0.7%	$8.43B +57.3%	$5.36B
EPS (Diluted)	$3.72 -51.3%	$7.64 +134.4%	$3.26 -16.6%	$3.91 -0.8%	$3.94 +57.6%	$2.50
Total Assets	$86.71B +6.5%	$81.41B +11.2%	$73.21B -1.6%	$74.44B -1.0%	$75.20B +3.6%	$72.55B
Total Debt	$15.96B +2.2%	$15.63B -0.9%	$15.76B -17.2%	$19.02B +1.2%	$18.80B +0.3%	$18.75B
Operating Cash Flow	$9.57B +11.8%	$8.56B +17.9%	$7.26B -24.2%	$9.58B -9.0%	$10.53B +33.3%	$7.90B
Free Cash Flow	$7.39B +16.4%	$6.35B +25.5%	$5.06B -35.2%	$7.80B -9.8%	$8.65B +51.1%	$5.72B

Get alerted when ABT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ABBOTT LABORATORIES including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABT

BlackRock, Inc.
$13.8B152,563,476 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.3B113,750,994 sh
STATE STREET CORP
$7.3B80,926,234 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$5.4B59,674,507 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.4B49,017,866 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.5B39,219,337 sh
Capital Research Global Investors
$3.3B36,908,990 sh
Capital International Investors
$3.1B34,654,113 sh
MORGAN STANLEY
$2.4B26,611,315 sh
NORGES BANK
$2.1B23,354,911 sh

Fund	Value	Shares
BlackRock, Inc.	$13.8B	152,563,476
VANGUARD CAPITAL MANAGEMENT LLC	$10.3B	113,750,994
STATE STREET CORP	$7.3B	80,926,234
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$5.4B	59,674,507
VANGUARD PORTFOLIO MANAGEMENT LLC	$4.4B	49,017,866
GEODE CAPITAL MANAGEMENT, LLC	$3.5B	39,219,337
Capital Research Global Investors	$3.3B	36,908,990
Capital International Investors	$3.1B	34,654,113
MORGAN STANLEY	$2.4B	26,611,315
NORGES BANK	$2.1B	23,354,911

Companies Similar to ABT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABBV

AbbVie Inc.

AI score

Highly similar · 49 shared holders

Capital Research Global Investors Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

JNJ

JOHNSON & JOHNSON

AI score

Highly similar · 47 shared holders

Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Grantham, Mayo, Van Otterloo & Co. LLC

SYK

STRYKER CORP

AI score

Highly similar · 40 shared holders

Capital Research Global Investors FLOSSBACH VON STORCH SE 1832 Asset Management L.P.

MDT

Medtronic plc

AI score

Highly similar · 35 shared holders

Capital Research Global Investors BARROW HANLEY MEWHINNEY & STRAUSS LLC STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

AMGN

AMGEN INC

AI score

Very similar · 42 shared holders

Capital Research Global Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Capital International Investors

MRK

Merck & Co., Inc.

AI score

Very similar · 45 shared holders

Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Grantham, Mayo, Van Otterloo & Co. LLC

PFE

PFIZER INC

AI score

Very similar · 30 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service PeakShares LLC

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 38 shared holders

Capital International Investors National Pension Service abrdn plc

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ABT on your watchlist

Track score changes the day ABBOTT LABORATORIES files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABT a good stock to buy?

13F Pro's AI-powered analysis of ABBOTT LABORATORIES (ABT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABT are available on the ABT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ABT is classified as a large company.

Which hedge funds own ABT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABBOTT LABORATORIES's investment landscape.